AgeX Therapeutics

AgeX Therapeutics is a biotech company engaged in the development and commercialization of novel therapeutics focused on aging. 

The company is building upon the foundation of its proprietary technologies, such as PureStem and induced Tissue Regeneration, to develop medicines targeting aging and related diseases. Through PureStem, the company claims to have the ability to generate pluripotent stem cell-derived young cells of any type for potential application in a range of degenerative diseases of aging. iTM is claimed to be the company's longevity platform intending to unlock cellular immortality and regenerative capacity to reverse age-related changes in the body.

Its product pipeline includes two cell-based and two iTR-based product candidates in development: AGEX-BAT1 and AGEX-VASC1.

AGEX-BAT1 is a cell therapy product candidate in the discovery stage of development utilizing PSC-derived brown adipocytes for the treatment of certain age-related metabolic disorders, such as type 2 (adult-onset) diabetes and obesity. AGEX-VASC1 is a cell-based therapy in the discovery stage of development, composed of young regenerative vascular-forming cells. 

The company was founded by leading gerontologist, bioentrepreneur, and Ph.D. holder Dr. Michael D. West,  a highly-regarded pioneer in cellular aging, stem cell research, telomerase, and cloning.

In August 2023, the company entered a merger agreement with Serina Therapeutics, a privately held, clinical-stage biotech company developing a pipeline of therapies for the treatment of Parkinson’s disease and other neurological diseases. Under this, Serina merged with a wholly-owned subsidiary of AgeX therapeutics in an all-stock transaction. The combined company continues under the “Serina Therapeutics” name and focuses on advancing Serina’s pipeline of small-molecule drug candidates targeting central nervous systems indications.

Funding and financials

The company recorded total revenue of USD 34 million in 2022, compared to USD 144 million in 2021 (77% decrease). This is due to absence of grant revenues in 2022, as opposed to 2021, where grant revenue was USD 104 million. Net loss reported for 2022 was USD 10.5 million, compared to the loss of USD 8.7 million recorded in the preceding year.